Program Book - Confex

More documents

Recommendations

Info

abstract keyword Index 2092, 2113, 2164, 2170, 2201, 2289, 2316, 2329, 2334, 2338, 2341, 2347, 2356, 2357, 2362, 2437, 2499, 2500, 2502, 2503, 2569, 2571, 2629 D damage 2263 death 112, 1154, 1392, 1456, 1599, 1712, 1715, 2443 decision analysis 118, 321, 743, 1851 dendritic cells 68, 993, 1008, 1009, 1010, 1011, 1345, 1636, 1673, 1701, 1706, 2095, 2430, 2496, 2504 denosumab 1098, 1103, 1107, 1108, 1631 dermatomyositis 224, 225, 226, 227, 228, 231, 234, 236, 241, 242, 243, 247, 249, 820, 822, 1678, 1846 dexamethasone 203 diabetes 99, 1022, 1163, 1284, 1602, 1856, 2355, 2584 diagnosis 19, 20, 148, 189, 200, 244, 284, 322, 357, 358, 378, 471, 551, 597, 600, 674, 811, 1043, 1057, 1105, 1307, 1308, 1320, 1523, 1581, 1608, 1617, 1901, 1927, 1956, 2019, 2022, 2040, 2261, 2291, 2402, 2633, 2638 diagnostic criteria 135, 137, 138, 177, 311, 314, 318, 474, 476, 517, 1033, 2386 diet 722 diffuse idiopathic skeletal hyperostosis (DISH) 2026 Digital X-ray Radiogrammetry (DXR) 1102, 2229 disability 109, 257, 293, 418, 679, 681, 795, 800, 909, 1206, 1539, 1855, 1863, 1872, 1873, 1982, 1983, 2119, 2124, 2137, 2273, 2294, 2490, 2509, 2515, 2612 Discontinuation 2596 disease-modifying antirheumatic drugs (DMARDs) 110, 113, 119, 123, 199, 255, 394, 409, 413, 429, 436, 459, 461, 504, 508, 540, 755, 904, 916, 952, 1179, 1207, 1220, 1229, 1253, 1269, 1581, 1877, 2055, 2133, 2193, 2197, 2198, 2222, 2223, 2247, 2404 , 2466, 2594, 2596, 2627, 2637 dopamine agonists 369 Doppler ultrasound 62, 173, 186, 195, 474, 810 drug interactions 1026 drug toxicity 803, 1219, 2448 dual energy x-ray absorptiometry (DEXA) 209, 213, 812, 869, 1106, 1113, 1617 E economics 132, 133, 140, 448, 628, 679, 878, 885, 889, 890, 895, 896, 902, 913, 914, 916, 919, 920, 1853, 2545, 2576 education, medical 83, 84, 85, 86, 87, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 1593, 1594, 1595, 1596, 1597, 1598, 1732 education, patient 91, 110, 149, 618, 743, 930, 1540, 1579, 1581, 1583, 1584, 1585, 1665, 1669, 2055, 2411 Ehlers-Danlos syndrome 2044 electronic communication 2057 email 2057 endothelial cells 28, 29, 36, 47, 78, 296, 724, 730, 731, 733, 1161, 1319, 1434, 1438, 1461, 1469, 1489, 2559B endothelial function 2263 Enthesitis 280, 515, 1300, 1346, 1347, 1702, 2486F enthesopathy 182, 213, 550, 2486F environmental factors 102, 768, 1372, 1893, 1895, 2139, 2161, 2171, 2172, 2173, 2574 Enzyme-Linked Immunoabsorbant Assays (ELISA) 38, 600, 1472, 2522 Eosinophilic Fasciitis (Shulman’s disease) 1451, 1955 epigenetics 252, 366, 385, 497, 645, 650, 775, 1426, 1427, 1672, 1673, 1922, 1923, 1928, 1929, 2517, 2519, 2520, 2605 etanercept 174, 258, 260, 274, 285, 330, 405, 406, 410, 429, 441, 457, 500, 515, 1216, 1217, 1223, 1233, 1236, 1249, 1284, 1288, 1290, 1321, 1830, 1884, 1931, 1932, 1961, 2030, 2197, 2198, 2239, 2512, 2534, 2619 ethics 2059 ethnic studies 293, 785, 1400, 2110, 2117 exercise 693, 722, 880, 1067, 1381, 1558, 1559, 1561, 1562, 1565, 1566, 1568, 1572, 1575, 1583, 1670, 1722, 1723, 2488, 2505, 2542, 2558, 2559B, 2613, 2614 extraarticular manifestations 717, 2130 extracellular matrix proteins 41, 1824, 1897, 1973 extracorporeal shockwave therapy 691 F familial Mediterranean fever 168, 297, 304, 541, 986, 1947, 1963, 1974, 2013, 2445, 2450, 2452 family studies 765, 767, 771, 1353, 1364, 1577, 2408, 2412 fatigue 125, 241, 242, 243, 925, 941, 1203, 1228, 1369, 1557, 1584, 1670, 1903, 1908, 2370, 2405, 2410, 2425, 2610 Fc receptors 562, 996, 1256 febuxostat 890, 891, 1022, 1031, 1604, 2048, 2583 female 514 fertility 1536, 2286 fever 306, 1961, 2447, 2452 fibroblast 35, 42, 46, 69, 374, 377, 381, 706, 832, 835, 1461, 1480, 1483, 1490, 1588, 1591, 1671, 1672, 1726, 1772, 1819, 1823, 1923, 2100, 2248, 2315, 2316, 2317, 2318, 2319, 2320, 2322, 2333, 2334, 2536, 2537, 2605, 2606, 2607 fibromyalgia 735, 736, 737, 738, 739, 740, 902, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 970, 971, 1566, 1577, 1605, 1606, 1607, 1608, 1609, 1610, 1899, 1900, 1901, 1902, 1903, 1904, 1905, 1906, 1907, 1908, 1909, 1910, 1911, 1912, 1913, 1914, 1915, 1916, 1917, 1942, 2026, 2066, 2408, 2409, 2421, 2564, 2567 folate 2467 foot disorders 194, 800, 1552, 1553, 1554, 1555, 1556, 1960, 1991, 2149, 2543, 2609 fracture 670, 805, 812, 829, 906, 1063, 1097, 1102, 1109, 1116, 1118, 1125, 1629, 1632, 1633, 1634, 2644 functional status 108, 147, 332, 333, 449, 505, 665, 742, 745, 811, 871, 1067, 1087, 1515, 1541, 1569, 1722, 1980, 1982, 1984, 1985, 1986, 1989, 1992, 2132, 2460, 2516, 2562 G galectin 1002 gastrointestinal complications 700, 716, 1058, 1455, 1459, 1498, 1527, 1961, 2000, 2565 gender 514 gene therapy 205, 1145, 1147 genetic disorders 155, 166, 301, 304, 305, 306, 641, 830, 1555, 1803, 1921, 1961, 2022, 2099, 2389, 2447 genetics 160 genomics 32, 150, 152, 154, 156, 157, 159, 163, 164, 165, 167, 253, 352, 359, 372, 399, 421, 481, 632, 645, 773, 819, 825, 841, 842, 996, 1340, 1352, 1361, 1366, 1423, 1431, 1446, 1494, 1496, 1497, 1637, 1677, 1678, 1680, 1681, 1682, 1686, 1688, 1701, 1832, 1921, 1927, 1931, 1934, 2139, 2142, 2152, 2156, 2159, 2162, 2165, 2166, 2311, 2313, 2325, 2329, 2390, 2475, 2476, 2478, 2479, 2517 geriatrics 1721 giant cell arteritis 189, 790, 1052, 1503, 1507, 1508, 1510, 1511, 1512, 1513, 1517, 1518, 1521, 1522, 1523, 1524, 2439, 2440, 2546 glomerulonephritis 793, 1417 glucocorticoids 29, 39, 79, 193, 233, 253, 282, 373, 419, 621, 756, 802, 804, 907, 914, 1102, 1126, 1127, 1128, 1129, 1145, 1198, 1219, 1228, 1258, 1269, 1633, 1972, 2131, 2463, 2464 glucosamine 67 glutamate 971 glycoproteins 14 gout 84, 207, 208, 209, 210, 211, 212, 213, 215, 216, 219, 220, 221, 222, 223, 887, 888, 889, 890, 892, 893, 894, 895, 896, 897, 898, 1013, 1014, 1015, 1016, 1017, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1054, 1083, 1592, 1599, 1600, 1601, 1602, 1604, 1617, 1618, 1619, 1620, 1621, 1622, 1935, 2048, 2058, 2074, 2579, 2581, 2582, 2583, 2584 growth factors 28, 35, 1349, 2031 390 2011 Program Book
H hand disorders 95, 962, 963, 1070, 1072, 1073, 1543, 1570, 1571, 1623, 1718, 1863 Health Assessment Questionnaire 109, 145, 270, 333, 351, 420, 1207, 1211, 1229, 1514, 1571, 1629, 2052, 2114, 2244, 2418, 2556 health behaviors 270, 626, 867, 868, 1558, 1576, 1850, 2024, 2032, 2111, 2404, 2542, 2558 health education 145, 626, 2111 heart disease 714, 761, 1155, 1171, 1183, 1477, 2121, 2450, 2588, 2606 hemochromatosis 171, 1803, 1960 hepatic disorders 1887 hepatitis 1316, 1528, 1529, 1530, 1753, 1945, 2238, 2620 Hip 1118 hip disorders 870, 879, 883, 1066, 1077, 1318, 1543, 1988, 1990, 2423 Hispanic patients 111, 1574 histone 46 hormones 663, 671, 876, 1039, 1133, 1425, 2016, 2129, 2353 HPV-58 477 human leukocyte antigens (HLA) 151, 516, 522, 781, 1038, 1341, 1344, 1352, 1353, 1355, 1357, 1360, 1362, 1363, 1364, 1441, 1452, 2157, 2161, 2171, 2310, 2330, 2343, 2396 human papillomavirus (HPV) 579, 1952 hydroxychloroquine 608, 613, 1168, 1234, 1409, 1410, 2067, 2077, 2304 hypermobility 861 hypertension 898, 1856, 2282 hypertriglyceridemia 2584 hyperuricemia 223, 1022, 1031, 1083, 1592, 1599, 1603, 1935, 2580, 2584 hypogammaglobulinemia 2374 I imaging techniques 31, 175, 184, 186, 187, 197, 198, 199, 200, 203, 204, 205, 206, 503, 506, 705, 734, 737, 787, 811, 945, 950, 954, 958, 964, 965, 968, 1175, 1297, 1298, 1347, 1390, 1467, 1798, 2456 imatinib 1460 immunodeficiency 170, 660, 758 immunoglobulin (IG) 14, 660, 662, 789, 793, 1435, 1641, 1713, 1740, 1822, 1924, 2186, 2380 impact 1538 induced regulatory T cells 849 infection 409, 413, 429, 433, 443, 462, 477, 688, 789, 806, 954, 1056, 1057, 1103, 1179, 1187, 1188, 1189, 1208, 1327, 1392, 1644, 1651, 1880, 1939, 1940, 1946, 1950, 1951, 1952, 2096, 2174, 2187, 2245, 2463, 2514, 2545, 2617, 2618 inflammation 28, 48, 49, 50, 58, 63, 69, 73, 75, 100, 166, 203, 246, 349, 355, 361, 364, 365, 367, 510, 522, 553, 573, 587, 729, 733, 748, 814, 816, 835, 853, 969, 975, 977, 980, 981, 984, 985, 988, 994, 1003, 1055, 1072, 1079, 1110, 1132, 1136, 1144, 1148, 1149, 1232, 1260, 1306, 1334, 1348, 1421, 1444, 1453, 1639, 1659, 1680, 1759, 1780, 1781, 1782, 1812, 1816, 1818, 1820, 1836, 1843, 1940, 1961, 1967, 2050, 2086, 2092, 2153, 2174, 2336, 2377, 2438, 2447, 2451, 2587 inflammatory arthritis 28, 33, 41, 74, 75, 155, 175, 186, 257, 294, 314, 347, 362, 440, 734, 954, 965, 983, 986, 1007, 1008, 1016, 1019, 1029, 1143, 1146, 1149, 1342, 1476, 1589, 1635, 1637, 1639, 1815, 1821, 1829, 1842, 1893, 1895, 1939, 2078, 2097, 2139, 2141, 2413, 2465, 2500, 2501, 2588 inflammatory bowel disease (IBD) 1266, 1705, 1759, 2116, 2530 infliximab 277, 406, 416, 435, 457, 459, 463, 510, 530, 546, 826, 1041, 1046, 1047, 1221, 1223, 1224, 1236, 1242, 1250, 1260, 1266, 1285, 1299, 1316, 1500, 1700, 1779, 1841, 1957, 1975, 2030, 2188, 2197, 2198, 2205, 2211, 2215, 2249, 2402, 2526, 2619, 2636 information technology 90, 264, 753, 758 insulin resistance 220, 419, 524, 1165, 1166, 1176, 2125 integrins 39, 41, 831, 998, 1681, 1796 interferons 59, 72, 78, 439, 456, 467, 486, 656, 698, 773, 820, 831, 853, 1009, 1147, 1372, 1404, 1407, 1423, 1424, 1426, 1428, 1429, 1433, 1438, 1443, 1446, 1655, 1685, 1703, 1762, 1807, 1808, 1812, 1819, 1834, 1835, 1919, 1941, 2178, 2289, 2329, 2353, 2429, 2470, 2475, 2478, 2494, 2496, 2504, 2547, 2601 interleukins (IL) 44, 52, 53, 58, 64, 73, 75, 76, 77, 79, 80, 156, 169, 273, 368, 383, 384, 386, 401, 451, 488, 563, 565, 571, 577, 651, 723, 774, 779, 791, 836, 968, 986, 1002, 1013, 1014, 1015, 1016, 1019, 1020, 1023, 1024, 1028, 1029, 1112, 1169, 1237, 1239, 1273, 1309, 1351, 1359, 1433, 1472, 1589, 1615, 1621, 1676, 1687, 1703, 1754, 1759, 1766, 1770, 1774, 1786, 1815, 1816, 1822, 1833, 1838, 1840, 1842, 1922, 1944, 1965, 1966, 1967, 1976, 2090, 2097, 2188, 2258, 2319, 2343, 2347, 2355, 2356, 2357, 2445, 2446, 2451, 2477, 2486D, 2500, 2501, 2607, 2622 intima medial thickness 760, 1071, 1156, 1167, 2587 Janus kinase (JAK) 407, 408, 409, 451, 718, 1136, 1213, 1215, 1267, 2192, 2210, 2230, 2569, 2592, 2627 Japan 1218 Japanese 406, 1220, 1965, 2629 job loss 795, 1539, 2292 joint destruction 173, 330, 352, 354, 400, 405, 418, 458, 460, 781, 1191, 1237, 1239, 1611, 1612, 1614, 1781, 1789, 1799, 1836, 2136, 2140, 2142, 2184, 2200, 2239, 2458 joint procedures 193, 921 juvenile arthritis 265, 276, 281, 287, 289, 290, 291, 293, 294, 300, 309, 511, 747, 863, 901, 1575, 2333, 2623 J juvenile dermatomyositis 32, 234, 245, 246, 247, 248, 252, 303, 747, 819, 992, 2007, 2012, 2019, 2027, 2034, 2039 juvenile idiopathic arthritis (JIA) 254, 255, 256, 257, 258, 259, 260, 262, 263, 264, 266, 267, 268, 269, 270, 272, 273, 274, 275, 277, 278, 279, 280, 282, 283, 284, 285, 286, 292, 295, 297, 307, 721, 750, 864, 865, 866, 956, 957, 958, 1578, 1685, 1686, 1688, 1875, 2492, 2621, 2622, 2625, 2626 juvenile idiopathic arthritis-enthesitis (ERA) 271, 1687, 2403 juvenile scleroderma 747, 2023, 2069, 2330 juvenile spondylarthropathy 747, 749 Kawasaki disease 296, 1533, 2040 kinase 44, 49, 420, 836, 1000, 1757, 1758, 1958, 2084, 2088, 2497, 2568 killer cell immunoglobulin-like receptors (KIR) 295, 781, 1354, 1355, 1362, 1363 knee 86, 89, 745, 797, 827, 830, 876, 877, 878, 883, 884, 885, 956, 957, 959, 960, 961, 1070, 1078, 1079, 1085, 1086, 1087, 1089, 1090, 1093, 1543, 1562, 1624, 1626, 1773, 1977, 1983, 1984, 1986, 1988, 1992, 1993, 1994, 1995, 1996, 1998, 1999, 2004, 2006, 2079, 2423, 2505, 2508, 2509, 2510, 2553, 2557 K L laboratory tests 24, 1841, 2600 large joints 178 leukocytes 72, 2570 Leukopenia, leukocytopenia, 1421, 2375, 2502 liability 2057 lipids 21, 121, 502, 519, 788, 1122, 1170, 1173, 1180, 1265, 1306, 1393, 1870, 1871, 2082, 2340, 2346, 2634 longitudinal studies 267, 273, 504, 593, 605, 798, 863, 940, 1392, 1474, 1513, 1542, 1712, 1721, 1888, 2142, 2443 lung 229, 689, 703, 706, 769, 1470, 1680, 1714, 1892, 2106, 2122, 2176, 2179, 2182, 2212, 2310, 2328, 2449, 2607 lupus dermatitis 1268 lupus nephritis 4, 553, 555, 556, 560, 563, 565, 567, 615, 620, 622, 627, 631, 656, 853, 984, 993, 1010, 1225, 1375, 1382, 1384, 1399, 1402, 1417, 1435, 1442, 1445, 1653, 1654, 1655, 1658, 1664, 1708, 1761, 1769, 2042, 2068, 2284, 2287, 2306, 2354, 2363, 2441, 2469, 2474, 2479, 2480, 2552, 2624 Lyme disease 975 lymph node 204, 734, 1635, 2082, 2089, 2177, 2493 lymphocytes 1959, 2607 M macrophage activation syndrome 831, 833, 1144, 1683, 1687, 2502 2011 Program Book 391 abstract keyword Index
Page 1 and 2:
program B O O K Pre-Conference Cour
Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
Page 5 and 6:
TABLE OF CONTENTS POLICIES Copyrigh
Page 7 and 8:
TABLE OF CONTENTS ACR Immunology Up
Page 9 and 10:
TABLE OF CONTENTS Vasculitis Poster
Page 11 and 12:
However, the ACR continues to requi
Page 13 and 14:
MEETING NAVIGATION GUIDE To navigat
Page 15 and 16:
Newsroom Located in room W175c, use
Page 17:
Guided Poster Tours Guided poster t
Page 20 and 21:
FRIDAY November 4, 2011 9:15 am Ult
Page 22 and 23:
SATURDAY, NOVEMBER 5, 2011 12:00 -
Page 24 and 25:
SATURDAY November 5, 2011 8:35 am T
Page 26 and 27:
SATURDAY November 5, 2011 Pain: Pat
Page 28 and 29:
SUNDAY November 6, 2011 SUNDAY, NOV
Page 30 and 31:
SUNDAY November 6, 2011 Upon comple
Page 32 and 33:
EXHIBITS 10:00 am - 5:00 pm INNOVAT
Page 34 and 35:
SUNDAY November 6, 2011 ARHP SPECIA
Page 36 and 37:
SUNDAY November 6, 2011 W179b Rheum
Page 38 and 39:
3:15 pm 732. Notch Signaling Pathwa
Page 40 and 41:
SUNDAY November 6, 2011 3:15 pm 756
Page 42 and 43:
SUNDAY November 6, 2011 Children’
Page 44 and 45:
Page 46 and 47:
3:30 pm Demonstration and Practice
Page 48 and 49:
Yasser M. El Miedany 1 , Maha El Ga
Page 50 and 51:
SUNDAY November 6, 2011 48 Musculos
Page 52 and 53:
Page 54 and 55:
SUNDAY November 6, 2011 52 4:55 pm
Page 56 and 57:
MONDAY, NOVEMBER 7, 2011 ACR/ARHP R
Page 58 and 59:
MONDAY November 7, 2011 W185a Scler
Page 60 and 61:
MONDAY November 7, 2011 Upon comple
Page 62 and 63:
Upon completion of this session, pa
Page 64 and 65:
MONDAY November 7, 2011 W187b Basic
Page 66 and 67:
MONDAY November 7, 2011 2:30 pm Cel
Page 68 and 69:
MONDAY November 7, 2011 Indianapoli
Page 70 and 71:
3:45 pm 1628. Association of Knee P
Page 72 and 73:
MONDAY November 7, 2011 Glostrup, C
Page 74 and 75:
MONDAY November 7, 2011 3:33 pm A R
Page 76 and 77:
MONDAY November 7, 2011 4:30 pm Ris
Page 78 and 79:
Institutet, Stockholm, Sweden, 6 Un
Page 80 and 81:
5:45 pm 1700. Successful Dose De-Es
Page 82 and 83:
MONDAY November 7, 2011 Michigan, A
Page 84 and 85:
MONDAY November 7, 2011 4:45 pm 172
Page 86 and 87:
MONDAY November 7, 2011 5:25 pm Imp
Page 88 and 89:
TUESDAY November 8, 2011 ARHP CONCU
Page 90 and 91:
TUESDAY November 8, 2011 9:25 am Is
Page 92 and 93:
ACR PRACTICE ISSUE 9:30 - 10:30 am
Page 94 and 95:
TUESDAY November 8, 2011 noon 2431.
Page 96 and 97:
TUESDAY November 8, 2011 W186b Vasc
Page 98 and 99:
ACR CLINICAL SYMPOSIA 2:30 - 4:00 p
Page 100 and 101:
TUESDAY November 8, 2011 3:45 pm 24
Page 102 and 103:
TUESDAY November 8, 2011 University
Page 104 and 105:
TUESDAY November 8, 2011 and Oncolo
Page 106 and 107:
Italy, 3 Hospital Universitario La
Page 108 and 109:
3:10 pm Case Study Diane V. Lacaill
Page 110 and 111:
• discuss the evidence to support
Page 112 and 113:
TUESDAY November 8, 2011 4:45 pm 25
Page 114 and 115:
5:15 pm 2532. Selection of Patients
Page 116 and 117:
TUESDAY November 8, 2011 ACR/ARHP C
Page 118 and 119:
WEDNESDAY, NOVEMBER 9, 2011 ACR/ARH
Page 120 and 121:
9:00 am Mechanisms of Thrombosis in
Page 122 and 123:
WEDNESDAY November 9, 2011 A. Kopec
Page 124 and 125:
WEDNESDAY November 9, 2011 9:15 am
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
WEDNESDAY November 9, 2011 Graduate
Page 132 and 133:
11:00 am The Process: Defining Appr
Page 134 and 135:
ACR Poster Session A 11. Myocardial
Page 136 and 137:
ACR Poster Session A 37. Regulation
Page 138 and 139:
ACR Poster Session A 64. Interleuki
Page 140 and 141:
ACR Poster Session A Mexico City, M
Page 142 and 143:
ACR Poster Session A 121. An Analys
Page 144 and 145:
ACR Poster Session A 146. National
Page 146 and 147:
ACR Poster Session A 165. Genome-Wi
Page 148 and 149:
ACR Poster Session A 185. US Examin
Page 150 and 151:
ACR Poster Session A Jones 1 , Andr
Page 152 and 153:
ACR Poster Session A Gerald J. D. H
Page 154 and 155:
ACR Poster Session A 258. Etanercep
Page 156 and 157:
ACR Poster Session A GA, 6 Hospital
Page 158 and 159:
ACR Poster Session A 305. Pathway-B
Page 160 and 161:
ACR Poster Session A 328. Near Miss
Page 162 and 163:
ACR Poster Session A 351. A Novel M
Page 164 and 165:
ACR Poster Session A Sugihara 6 , K
Page 166 and 167:
ACR Poster Session A 398. Rituximab
Page 168 and 169:
ACR Poster Session A & Johnson Phar
Page 170 and 171:
ACR Poster Session A 436. Predicted
Page 172 and 173:
ACR Poster Session A Tomomi Tsuru 1
Page 174 and 175:
ACR Poster Session A 479. Follow up
Page 176 and 177:
ACR Poster Session A 496. A Chimeri
Page 178 and 179:
ACR Poster Session A 518. Associati
Page 180 and 181:
ACR Poster Session A Piestany, Slov
Page 182 and 183:
ACR Poster Session A 576. Fn14 Defi
Page 184 and 185:
ACR Poster Session A 593. Plasma Le
Page 186 and 187:
ACR Poster Session A 611. Why Do Lu
Page 188 and 189:
ACR Poster Session A 634. Associati
Page 190 and 191:
ACR Poster Session A Alarcon-Riquel
Page 192 and 193:
ACR Poster Session A Laboratories,
Page 194 and 195:
ACR Poster Session A Movsisyan, Lid
Page 196 and 197:
ACR Poster Session A Th1 Cells Expa
Page 198 and 199:
ACR/ARHP Poster Session B College o
Page 200 and 201:
ACR/ARHP Poster Session B 920. Econ
Page 202 and 203:
ACR/ARHP Poster Session B Study. A.
Page 204 and 205:
ACR/ARHP Poster Session B 974. Dise
Page 206 and 207:
ACR/ARHP Poster Session B 1001. Mic
Page 208 and 209:
ACR/ARHP Poster Session B 206 Khann
Page 210 and 211:
ACR/ARHP Poster Session B 208 Pulmo
Page 212 and 213:
ACR/ARHP Poster Session B Swearinge
Page 214 and 215:
ACR/ARHP Poster Session B 212 Felds
Page 216 and 217:
ACR/ARHP Poster Session B 214 Corbi
Page 218 and 219:
ACR/ARHP Poster Session B 1161. End
Page 220 and 221:
ACR/ARHP Poster Session B 1182. Uri
Page 222 and 223:
ACR/ARHP Poster Session B 1205. A S
Page 224 and 225:
ACR/ARHP Poster Session B 222 Murth
Page 226 and 227:
ACR/ARHP Poster Session B San Diego
Page 228 and 229:
ACR/ARHP Poster Session B 1266. Eva
Page 230 and 231:
ACR/ARHP Poster Session B 1296. Pat
Page 232 and 233:
ACR/ARHP Poster Session B 230 1320.
Page 234 and 235:
ACR/ARHP Poster Session B 1348. Syn
Page 236 and 237:
ACR/ARHP Poster Session B 1375. Ant
Page 238 and 239:
ACR/ARHP Poster Session B 1398. Cli
Page 240 and 241:
ACR/ARHP Poster Session B Baltimore
Page 242 and 243:
ACR/ARHP Poster Session B 1451. Ele
Page 244 and 245:
ACR/ARHP Poster Session B Sclerosis
Page 246 and 247:
ACR/ARHP Poster Session B 1496. Evi
Page 248 and 249:
ACR/ARHP Poster Session B 1518. Pro
Page 250 and 251:
ACR/ARHP Poster Session B Hagen 1 ,
Page 252 and 253:
ACR/ARHP Poster Session B ARHP Clin
Page 254 and 255:
ACR/ARHP Poster Session C Karl Eger
Page 256 and 257:
ACR/ARHP Poster Session C Tampere S
Page 258 and 259:
ACR/ARHP Poster Session C 256 1 Jun
Page 260 and 261:
ACR/ARHP Poster Session C Universit
Page 262 and 263:
ACR/ARHP Poster Session C 1864. Epi
Page 264 and 265:
ACR/ARHP Poster Session C 262 Hospi
Page 266 and 267:
ACR/ARHP Poster Session C 2 Biogen
Page 268 and 269:
ACR/ARHP Poster Session C 1945. Cir
Page 270 and 271:
ACR/ARHP Poster Session C 268 1974.
Page 272 and 273:
ACR/ARHP Poster Session C 2003. Eff
Page 274 and 275:
ACR/ARHP Poster Session C Hosp Gast
Page 276 and 277:
ACR/ARHP Poster Session C Toronto,
Page 278 and 279:
ACR/ARHP Poster Session C Francisco
Page 280 and 281:
ACR/ARHP Poster Session C 2105. Inc
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
ACR/ARHP Poster Session C 2217. Lon
Page 292 and 293:
ACR/ARHP Poster Session C Research
Page 294 and 295:
ACR/ARHP Poster Session C 2258. sIL
Page 296 and 297:
ACR/ARHP Poster Session C 2290. The
Page 298 and 299:
Page 300 and 301:
ACR/ARHP Poster Session C 2345. IL-
Page 302 and 303:
ACR/ARHP Poster Session C 2376. Gra
Page 304 and 305:
ACR/ARHP Poster Session C 2399. Spe
Page 306 and 307:
REF Industry Roundtable-supported S
Page 308 and 309:
REF Industry Roundtable-supported S
Page 310 and 311:
Industry-supported POST-CONFERENCE
Page 312 and 313:
CERTIFICATES OF CME CREDIT OR PARTI
Page 314 and 315:
2011 ACR/ARHP Annual Meeting Leader
Page 316 and 317:
2011 ACR/ARHP Annual Meeting Leader
Page 318 and 319:
EXHIBITORS Abbott Pharmaceuticals B
Page 320 and 321:
EXHIBITORS Lippincott, Williams and
Page 322 and 323:
acknowledgements The ACR, the ARHP
Page 324 and 325:
Invited Speaker /Moderator Index 32
Page 326 and 327:
Page 328 and 329:
Invited Speaker /Moderator Index Ev
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Invited Speaker /Moderator Index Mu
Page 336 and 337:
Invited Speaker /Moderator Index Om
Page 338 and 339:
Invited Speaker /Moderator Index St
Page 340 and 341:
Invited Speaker /Moderator Index Wi
Page 342 and 343: aBSTRACT author Index 340 Alpers, C
Page 344 and 345: aBSTRACT author Index Bawa, WA 259
Page 346 and 347: aBSTRACT author Index 344 Broder, A
Page 348 and 349: aBSTRACT author Index 346 Chaves, L
Page 350 and 351: aBSTRACT author Index 348 Dalbeth,
Page 352 and 353: aBSTRACT author Index Eastman, PS 3
Page 354 and 355: aBSTRACT author Index 352 Fragoso-L
Page 356 and 357: aBSTRACT author Index Gordon, C 4,
Page 358 and 359: aBSTRACT author Index Hemmati, I 13
Page 360 and 361: aBSTRACT author Index 358 Ishigatsu
Page 362 and 363: aBSTRACT author Index 360 Keeling,
Page 364 and 365: aBSTRACT author Index 362 Kumar, V
Page 366 and 367: aBSTRACT author Index 364 Lim, M 13
Page 368 and 369: aBSTRACT author Index 366 Marshall,
Page 370 and 371: aBSTRACT author Index 368 MMF/AZA L
Page 372 and 373: aBSTRACT author Index 370 Noel, D 1
Page 374 and 375: aBSTRACT author Index 372 Pawlita,
Page 376 and 377: aBSTRACT author Index 374 Ramos, I
Page 378 and 379: aBSTRACT author Index 376 Rönnblom
Page 380 and 381: aBSTRACT author Index 378 Shaykevic
Page 382 and 383: aBSTRACT author Index Su, J 22, 139
Page 384 and 385: aBSTRACT author Index 382 Tomcik, M
Page 386 and 387: aBSTRACT author Index 384 Villeneuv
Page 388 and 389: aBSTRACT author Index 386 Wu, X 650
Page 390 and 391: abstract keyword Index 388 18FDG PE
Page 394 and 395: abstract keyword Index 392 macropha
Page 396 and 397: abstract keyword Index 387, 388, 38
Page 398 and 399: Abstract Moderator disclosure A Ano
Page 400 and 401: Abstract Moderator disclosure Jonas
Page 402 and 403: V van der Heijde, Desiree, MD, PhD
Page 404 and 405: Notes 402 2011 Program Book
Page 406 and 407: immunosuppressive agents is not rec
Page 408: In appropriate patients with psoria
show all

Program Book - Confex

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?